Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study - PubMed
4 hours ago
- #Multiple Myeloma
- #Real-World Evidence
- #Treatment Comparison
- This real-world study compares DRd (daratumumab, lenalidomide, dexamethasone) and DVd (daratumumab, bortezomib, dexamethasone) in relapsed/refractory multiple myeloma (RRMM) using propensity score matching.
- Results show DRd significantly prolonged time to next treatment (median 32.6 vs. 17.7 months) and improved 5-year overall survival (58.4% vs. 52.3%) compared to DVd.
- DRd was associated with higher grade ≥3 neutropenia (27.7% vs. 12.5%), while DVd had higher grade ≥3 anemia (12.9% vs. 7.6%); other adverse events were infrequent (<10%).
- The study concludes that DRd offers superior effectiveness and manageable toxicity, suggesting it may be the preferred regimen for RRMM, warranting randomized head-to-head trials.